Orqis Begins Cancion Therapy Trial Enrollment, Mulls Future Indications
This article was originally published in The Gray Sheet
Executive Summary
Orqis Medical has enrolled the first patient in the MOMENTUM pivotal trial of its Cancion CRS cardiac recovery system, according to Medical Director Marvin Konstam, MD, Tufts-New England Medical Center
You may also be interested in...
Financings In Brief
Orqis Medical: Lake Forest, Calif.-based firm will use proceeds from a $22.7 mil. Series D financing to finish the firm's pivotal, 200-patient, multi-site MOMENTUM trial evaluating Cancion CRS therapy. Orqis says Cancion is the first therapy for congestive heart failure based on continuous aortic blood flow augmentation to the descending aorta (1"The Gray Sheet" Oct. 11, 2004, p. 26). The firm expects to file a PMA in the second half of 2006 for an acute decompensation heart failure indication. Financing proceeds will also support pre-clinical work for Orqis' Exeleras CRS therapy, designed as a long-term implantable therapeutic recovery solution for patients suffering from chronic heart failure. Human trials are several years away, the firm says. New investors Boston Scientific and Lighthouse Capital Partners participated in the financing; other investors included Domain Associates, Johnson & Johnson Development Corporation and HealthCare Ventures...
Financings In Brief
Orqis Medical: Lake Forest, Calif.-based firm will use proceeds from a $22.7 mil. Series D financing to finish the firm's pivotal, 200-patient, multi-site MOMENTUM trial evaluating Cancion CRS therapy. Orqis says Cancion is the first therapy for congestive heart failure based on continuous aortic blood flow augmentation to the descending aorta (1"The Gray Sheet" Oct. 11, 2004, p. 26). The firm expects to file a PMA in the second half of 2006 for an acute decompensation heart failure indication. Financing proceeds will also support pre-clinical work for Orqis' Exeleras CRS therapy, designed as a long-term implantable therapeutic recovery solution for patients suffering from chronic heart failure. Human trials are several years away, the firm says. New investors Boston Scientific and Lighthouse Capital Partners participated in the financing; other investors included Domain Associates, Johnson & Johnson Development Corporation and HealthCare Ventures...
Heart Failure Devices Must Be “Smarter,” Reverse Disease – HFSA President
Heart failure devices should reverse the underlying biochemical causes of disease instead of merely supporting or replacing a dysfunctional part, according to Heart Failure Society of America President Marvin Konstam, MD, New England Heart Center